PFE Stock Price - Pfizer Inc - (PFE)
- Prev. Close: 35.73
- Open: 35.91
- Daily Range: 35.87 - 36.46
PFE NEWS FROM BIDNESS ETC
Pfizer Inc. (PFE) Surges On Q215 Earnings
Pfizer announces earnings for the second quarter of 2015
Earnings Whispers: Pfizer Inc. (PFE) & United Parcel Service, Inc. (UPS...
Bidness Etc highlights the earnings whispers for Pfizer and United Parcel Service, as the two companies look to release their second-quarter earnings ...
Pfizer Inc. (PFE) Q2 Earnings: What To Expect?
Analysts expect an increase in profits, but a drop in revenue as sales of the company’s major drugs continue to decline
- Here’s How Pfizer Inc., GlaxoSmithKline plc Vaccines Deal Works For Both ...
- Merck & Co., GlaxoSmithKline plc, & Others Expected To Be Neck-And-...
- GlaxoSmithKline plc (ADR) Mega-Merger Talk: Johnson & Johnson, Roche Ho...
- Pfizer Inc. (PFE) To Boost Production In China With $95 Million Plant
- Insider Selling: Pfizer Inc. (PFE), Goldman Sachs Group Inc (GS), Celgene C...
- Pfizer Inc. Wards Off Another Birth Defect Case Against Antidepressant Zolo...
- Pfizer Inc. Still In Trouble Over Anti-depressant Drug Zoloft And Birth Def...
- Insider Selling: Pfizer Inc. (PFE), Anthem Inc (ANTM), And CVS Health Corp ...
- Pfizer Inc. (PFE) Split Could Be Announced By 2015-2016: JPMorgan
More News From Bidness
Pfizer Inc. Interested In Acquiring French Biotech Firm... PUBLISHED: Jun 1, 2015 at 6:54 am ESTPfizer Inc. Gets FDA Green Signal For The First Drug To... PUBLISHED: May 29, 2015 at 6:25 am ESTDriven By Pfizer Inc. And Novartis AG (ADR), Global Bre... PUBLISHED: May 23, 2015 at 9:06 am ESTPfizer Inc. Mega-Merger Talk: The Speculated Targets PUBLISHED: May 22, 2015 at 8:04 am EST
Pfizer Inc.-GlaxoSmithKline Merger Talk: Deutsche Bank Speculates “PfizerKline” PUBLISHED: May 20, 2015 at 11:29 am EST
Pfizer Inc. To See Boosting Revenues On New Drugs Growth Through 2020 PUBLISHED: May 20, 2015 at 11:29 am EST
The company’s stock, expected to soar on significant boost in revenues fuelled by new drugs growth in the coming years, is bound to reap high returns for the investors in the long run; Pfizer’s stock thus presents a perfect buying opportunity rig...READ MORE
Inhaled Insulin: How MannKind Corporation Can Make It Work Better Than Pfizer Inc. PUBLISHED: May 18, 2015 at 6:37 am EST
Mannkind’s inhaled insulin product Afrezza has a better chance at success than Pfizer’s failure in the field nine years agoREAD MORE
Early ORR For Pfizer (PFE) And Merck’s (MRK) Avelumab In Lung Is Unimpressive: SunTrust PUBLISHED: May 17, 2015 at 9:09 am EST
SunTrust believes that Avelumab’s early results related to lung cancer are unimpressive, while the outcome for ovarian cancer is averageREAD MORE
Pfizer Inc., Merck KGaA (ADR) To Set Strong Foothold In Cancer Immunotherapy Drugs Market PUBLISHED: May 14, 2015 at 10:14 am EST
The fast-expanding class of immunotherapy drugs presents a high-growth opportunity for both Pfizer and Merck KGaA. If tapped into at the right time, the market can yield high revenues for both parties in the long runREAD MORE
Biogen Inc (BIIB) May Soon Trump Pfizer In Global CNS Drug Sales PUBLISHED: May 13, 2015 at 6:23 am EST
Biogen saw 46% growth in global central nervous system drug sales in 2014, coming almost neck-and-neck with Pfizer, as per GlobalDataREAD MORE
Pfizer Inc. (PFE) Attains Stake In AM-Pharma; Locks In Right To Buy Whole Company PUBLISHED: May 12, 2015 at 8:24 am EST
Pzifer has acquired a minority stake in AM-Pharma and has also gained the exclusive option to acquire the whole companyREAD MORE